tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Neuritis D009443 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bone Diseases D001847 4 associated lipids
Pain, Intractable D010148 4 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Erythema Nodosum D004893 5 associated lipids
Hematoma D006406 5 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Respiration Disorders D012120 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Complications D011183 5 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Sclerosis D012598 5 associated lipids
Mastocytosis D008415 5 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Tinea D014005 5 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Mouth Diseases D009059 5 associated lipids
Liver Failure D017093 5 associated lipids
Osteomalacia D010018 5 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Trypanosomiasis D014352 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Infection D007239 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Graves Disease D006111 6 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Gynecomastia D006177 6 associated lipids
Angioedema D000799 6 associated lipids
Pancytopenia D010198 6 associated lipids
Thrombophlebitis D013924 6 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Heart Injuries D006335 6 associated lipids
Coronary Stenosis D023921 6 associated lipids
Liver Abscess D008100 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Pericarditis D010493 6 associated lipids
Blindness D001766 6 associated lipids
Alopecia Areata D000506 6 associated lipids
Gliosis D005911 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Dyslipidemias D050171 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Chronic Disease D002908 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Metaplasia D008679 7 associated lipids
Hepatitis C D006526 7 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Behcet Syndrome D001528 7 associated lipids
Dementia, Vascular D015140 7 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Facial Dermatoses D005148 7 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Tachycardia D013610 7 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Folliculitis D005499 7 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Lupus Nephritis D008181 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Fistula D005402 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Thyroid Diseases D013959 8 associated lipids
Opportunistic Infections D009894 8 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Cicatrix D002921 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Sinusitis D012852 9 associated lipids
Leukocytosis D007964 9 associated lipids
Urination Disorders D014555 9 associated lipids
Hypertension, Renal D006977 9 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Blackham A and Griffiths RJ The effect of FK506 and cyclosporin A on antigen-induced arthritis. 1991 Clin. Exp. Immunol. pmid:1718639
Fukuda T et al. Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. 1991 Int. Arch. Allergy Appl. Immunol. pmid:1718889
Meiser BM et al. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. 1991 Lancet pmid:1719321
Jorgensen WL Rusting of the lock and key model for protein-ligand binding. 1991 Science pmid:1719636
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Keenan RJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. 1991 Transplantation pmid:1719668
Strasser S et al. The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. 1991 Transplant. Proc. pmid:1703709
Ryu S and Yasunami Y Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. 1991 Transplant. Proc. pmid:1703710
Alejandro R et al. Combined liver-islet allotransplantation in man under FK 506. 1991 Transplant. Proc. pmid:1703712
Ito T et al. The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. 1991 Transplant. Proc. pmid:1703716
Zheng B et al. Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. 1991 Transplant. Proc. pmid:1703717
Yabuuchi H et al. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. 1991 Transplant. Proc. pmid:1703718
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Ericzon BG et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. 1991 Transplant. Proc. pmid:1721273
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Ali Shah I et al. Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. 1991 Transplant. Proc. pmid:1721276
Moochhala SM et al. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721277
Sumpio BE and Phan S Nephrotoxic potential of FK 506. 1991 Transplant. Proc. pmid:1721278
Pichard L et al. Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. 1991 Transplant. Proc. pmid:1721279
Connelly PR Thermodynamics of interaction of FK 506-binding protein and its ligands. 1991 Transplant. Proc. pmid:1721304
Donnelly JG and Soldin SJ Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. 1991 Transplant. Proc. pmid:1721305
Rosborough SL et al. Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. 1991 Transplant. Proc. pmid:1721306
Zeevi A et al. In vitro assessment of FK 506 immunosuppressive activity in transplant patients. 1991 Transplant. Proc. pmid:1721307
Katz HR et al. Mast cell biochemical and functional heterogeneity. 1991 Transplant. Proc. pmid:1721308
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Lewis WD et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. 1991 Transplant. Proc. pmid:1721336
Woodle ES et al. FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. 1991 Transplant. Proc. pmid:1721337
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
McDiarmid SV et al. FK 506 rescue therapy in liver transplantation: outcome and complications. 1991 Transplant. Proc. pmid:1721339
Rucay P et al. FK 506 rescue therapy for refractory acute rejection in five liver recipients. 1991 Transplant. Proc. pmid:1721340
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Uemoto S et al. Experience with FK 506 in living related donor liver transplantation. 1991 Transplant. Proc. pmid:1721342
Tzakis AG et al. FK 506 versus cyclosporine in pediatric liver transplantation. 1991 Transplant. Proc. pmid:1721343
Darras FS et al. Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721368
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Fries D et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. 1991 Transplant. Proc. pmid:1721370
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Fung JJ et al. Adverse effects associated with the use of FK 506. 1991 Transplant. Proc. pmid:1721372
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721374
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Lagodziński Z et al. Effect of FK 506 on B-cell responses. 1991 Transplant. Proc. pmid:1703359
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Thomson AW et al. The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. 1991 Transplant. Proc. pmid:1703361
Mieles L et al. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. 1991 Transplant. Proc. pmid:1703362
Warty V et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. 1991 Transplant. Proc. pmid:1703363
Kusne S et al. Early infections in kidney transplant recipients under FK 506. 1991 Transplant. Proc. pmid:1703364
Abu-Elmagd KM et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. 1991 Transplant. Proc. pmid:1721404
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Pirsch JD et al. Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. 1991 Transplant. Proc. pmid:1721406
Shinozuka H et al. Effect of FK 506 on experimental liver carcinogenesis. 1991 Transplant. Proc. pmid:1721407
Pelekanou V et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. 1991 Transplant. Proc. pmid:1721408
Tai J et al. In vivo and in vitro effect of FK 506 on rat Leydig cell function. 1991 Transplant. Proc. pmid:1721409
Ricordi C et al. Human islet allotransplantation under FK 506. 1991 Transplant. Proc. pmid:1721410
Tze WJ et al. Long-term survival of islet allografts in diabetic rats treated with FK 506. 1991 Transplant. Proc. pmid:1721411
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
Griffiths EJ and Halestrap AP Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. 1991 Biochem. J. pmid:1706598
Brabletz T et al. The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. 1991 Nucleic Acids Res. pmid:1707162
Iwaki Y et al. Replacement of donor lymphoid tissue in small-bowel transplants. 1991 Lancet pmid:1707470
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Lin CS et al. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. 1991 Cell. Immunol. pmid:1707760
Vincent SH et al. Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. 1991 Biochem. Pharmacol. pmid:1708254
Kitahara S et al. Lymphoproliferative disorders after FK 506. 1991 Lancet pmid:1708846
Ito T et al. Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. 1991 Transplant. Proc. pmid:1721437
DeValeria PA et al. FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. 1991 Transplant. Proc. pmid:1721438
Jiang H et al. Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. 1991 Transplant. Proc. pmid:1721439
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Katayama Y et al. Immunosuppressive effects of FK 506 in rat lung transplantation. 1991 Transplant. Proc. pmid:1721441
Yokomise H et al. Immunosuppressive effects of FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721442
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
McAlpine JB et al. Revised NMR assignments for rapamycin. 1991 J. Antibiot. pmid:1712766
Banerji SS et al. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. 1991 Mol. Cell. Biol. pmid:1712901
Markus PM et al. FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. 1991 Surgery pmid:1713358
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Armitage JM et al. Preliminary experience with FK506 in thoracic transplantation. 1991 Transplantation pmid:1713363
Nicoletti F et al. FK-506 prevents diabetes in diabetes-prone BB/Wor rats. 1991 Int. J. Immunopharmacol. pmid:1722192
Starzl TE et al. [Clinical experience with FK 506]. 1991 Presse Med pmid:1722311
Granelli-Piperno A and McHugh P Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1722332
Nelson PA et al. cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. 1991 Gene pmid:1722474
Chen MF et al. The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. 1991 Immunol. Lett. pmid:1722778
Sakai K et al. The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. 1991 Brain Res. pmid:1723023
Forrest MJ et al. FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. 1991 Biochem. Pharmacol. pmid:1716098
Weaver JL et al. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. 1991 Immunopharmacol Immunotoxicol pmid:1723084
DiLella AG and Craig RJ Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. 1991 Biochemistry pmid:1716149
McKeon F When worlds collide: immunosuppressants meet protein phosphatases. 1991 Cell pmid:1716181
Nakahama H et al. Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. 1991 J. Cardiovasc. Pharmacol. pmid:1725322
Romanowski P et al. [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. 1991 Postepy Biochem. pmid:1725924
Altmeyer A et al. Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. 1991 Int. J. Immunopharmacol. pmid:1726093
Gordon RD et al. Liver transplantation at the University of Pittsburgh, 1984 to 1990. 1991 Clin Transpl pmid:1726458
Jamieson NV et al. Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. 1991 Clin Transpl pmid:1726459
Takahara S et al. Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. 1991 J Clin Lab Immunol pmid:1726566
Lane WS et al. Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. 1991 J. Protein Chem. pmid:1718307
Stötter H and Lotze MT Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. 1991 Arch Surg pmid:1726819
James DG Which immunomodulator? 1991 Br J Clin Pract pmid:1718384
Karlsson H and Nässberger L FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. 1991 J Clin Lab Immunol pmid:1726895